BioCardia files 2nd FDA IDE bid for CardiAMP chronic myocardial ischemia, refractory angina study

This article was originally published here

BioCardia (NSDQ:BCDA) said today it filed for a second FDA investigational device exemption to launch a trial of its CardiAMP cell therapy of chronic myocardial ischemia and refractory angina as it seeks a second indication.

The San Carlos, Calif.-based company’s CardiAMP therapy uses autologous cells to treat chronic myocardial ischemia, and is designed to stimulate the body’s natural healing response.

Read the whole story on our Sister Site, Drug Delivery Business

The post BioCardia files 2nd FDA IDE bid for CardiAMP chronic myocardial ischemia, refractory angina study appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply